Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Trial to Assess the Safety and Efficacy of Topical Salbutamol in Healthy Volunteers. (SSCART)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03514615
Recruitment Status : Active, not recruiting
First Posted : May 2, 2018
Last Update Posted : February 7, 2019
Sponsor:
Collaborators:
Leicester Clinical Trials Unit
University of Leicester
Medical Research Council
Information provided by (Responsible Party):
University Hospitals, Leicester

Brief Summary:
This will be a single centre, double-blind, placebo (vehicle) controlled, randomised, dose escalation trial. Three concentrations of topical salbutamol gel will be compared, in a group-wise fashion, with a placebo administration at one incision site on each arm of the trial subjects. Each participant will be allocated to only one dosing group. The treatments will be paired anatomically so that for each pair of sites, one closed incision site will receive the active substance, while the other will receive placebo.

Condition or disease Intervention/treatment Phase
Scarring Procedure: Incision Drug: Active gel Drug: Placebo gel Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 45 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Double Blind, Placebo Controlled, Randomised Dose Escalation Trial to Investigate the Safety and Efficacy of Topical Salbutamol in the Improvement of Scar Appearance When Applied to Approximated Wound Margins in Healthy Volunteers.
Actual Study Start Date : January 10, 2018
Actual Primary Completion Date : July 20, 2018
Estimated Study Completion Date : July 14, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Scars

Arm Intervention/treatment
Placebo Comparator: Placebo Gel
Each participant will be allocated to only one dosing group. The treatments will be paired anatomically so that for each pair of sites, one closed incision site will receive the active gel and the other placebo.
Procedure: Incision
A skin incision will be made on the medial aspect of the upper arm.

Drug: Placebo gel
The incision site on the other arm will be dosed with placebo gel.

Experimental: Active Gel
Each participant will be allocated to only one dosing group. The treatments will be paired anatomically so that for each pair of sites, one closed incision site will receive the active gel and the other placebo.
Procedure: Incision
A skin incision will be made on the medial aspect of the upper arm.

Drug: Active gel
The incision site on one arm will be dosed with the active gel.




Primary Outcome Measures :
  1. Peak plasma concentration [ Time Frame: 24 hours ]
    The primary trial endpoint will be the peak plasma concentration of salbutamol at day 0.


Secondary Outcome Measures :
  1. Peak Plasma concentration 2 [ Time Frame: 10 days ]
    The peak plasma concentration of salbutamol at day 10.

  2. Efficacy of treatment using the Global Scar Comparison Scale [ Time Frame: 12 months ]
    Improvement in scar appearance will be assessed using a global appearance scale, referred to as the "Global Scar Comparison Scale" (GSCS), which seeks to assess which one of a pair of scars is visually improved compared to the other. The scale is based on a 200mm Visual Analogue Scale, with "0"mm at the centre indicating no difference between the scars. The extremes of the scale -100mm to +100mm are reserved for one scar becoming imperceptible compared to the other. The assessment will be performed by both the patient and investigator independently at months 7, 9 and 12.

  3. Efficacy of treatment using the Patient Observer Scar Assessment Scale [ Time Frame: 12 months ]
    Improvement in scar appearance will be assessed using the "Patient and Observer Scar Assessment Scale" (POSAS) which is a composite scale made up of sub-scales, that measure 12 items numerically (6 by the patient; scar pain, scar itch, colour differences, scar stiffness, scar thickness and scar irregularity) and six items scored by the investigator (vascularity, pigmentation, thickness, relief, pliability and surface area). The patient sub-scales are scored 1-10 where 1="no, not at all" and 10 = "yes, very much". The clinical sub-scores are also scored 1-10 with 1=normal skin and 10=worst scar imaginable. POSAS is calculated as a total score of all sub-scores. The assessment will be performed by both the patient and investigator independently at months 7, 9 and 12.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Able, in the opinion of the investigator, and willing to give informed consent
  2. Aged 18 - 50 inclusive, with both arms
  3. Participants registered on The Over Volunteering Prevention System (TOPS) or equivalent in Leicester.
  4. Body mass index within the range 15.0-35.0 kg/m2. Inclusive (i.e. ≥ 15.0 and ≤ 35.0)
  5. In the opinion of the investigator, clinically acceptable results for the laboratory tests specified in the trial protocol (see Protocol Section 11.2). All laboratory tests must be performed within 28 days of the subject's first trial dose administration.
  6. Women of child bearing potential (WOCBP) must be using a highly effective means of contraception and agree to do so from at least the screening visit until trial end or completion of the trial.

Exclusion Criteria:

  1. On direct questioning, have evidence of Left/Right Confusion.
  2. On direct questioning and/or physical examination a history or evidence of keloid scarring.
  3. On direct questioning have a family history of keloid scarring.
  4. Tattoos or previous scars within 3cm of the area to be incised during the trial.
  5. Surgery in the area to be incised and have surgical scars within 3cm of this area.
  6. History of a bleeding disorder or who are receiving anti-coagulant or anti-platelet therapy.
  7. On direct questioning and physical examination, have evidence of any past or present clinically significant disease that may affect the endpoints of the trial. For example: Coagulation disorders, diabetes, immuno-mediated conditions or allergies (including allergic contact dermatitis).
  8. Subjects with a clinically significant skin disorder (dermatitis, eczema, psoriasis) that is chronic or currently active and which the Investigator considers will adversely affect the healing of the acute wounds or involves the areas to be examined in this trial.
  9. Any clinically significant medical condition or history that would impair wound healing including:

    • Rheumatoid arthritis.
    • Chronic renal impairment for their age.
    • Hepatic impairment (LFTs >3 times upper limit of normal).
    • Congestive heart failure.
    • Pre-existing ischemic heart disease
    • Pulmonary hypertension
    • Hypertrophic obstructive cardiomyopathy
    • Aortic stenosis
    • Current active malignancy or history of malignancy in the last 5 years.
    • Immunosuppression or chemotherapy within the last 12 months.
    • A history of radiotherapy at the areas to be studied.
    • Diabetes mellitus.
    • Subjects with proven diagnosis of thyroid disease
  10. A history of hypersensitivity to any of the drugs or dressings used in this trial
  11. Currently taking other prescribed treatments:

    • All corticosteroids, whether topically applied or systemic;
    • Any salbutamol containing preparations
    • Other beta-agonists, such as salmeterol
    • Any beta-blockers, such as propranolol
    • Other beta antagonists
    • Adrenaline
  12. Undergoing investigations or changes in management for an existing medical condition.
  13. History of drug abuse, including cocaine, amphetamines, methamphetamines, opiates or benzodiazepines.
  14. In the opinion of the investigator, are unlikely to complete the trial for whatever reason.
  15. Any clinically significant neurological impairment or disease, including body dysmorphia.
  16. At entry into the trial, any active infection.
  17. Pregnant or lactating or planning to become pregnant during the duration of the trial.
  18. Not involved with any other clinical trial of medicinal product at the time of consent or 3 months prior.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03514615


Locations
Layout table for location information
United Kingdom
Leicester Royal Infirmary
Leicester, United Kingdom
Sponsors and Collaborators
University Hospitals, Leicester
Leicester Clinical Trials Unit
University of Leicester
Medical Research Council
Investigators
Layout table for investigator information
Principal Investigator: Graham Johnston University of Leicester

Layout table for additonal information
Responsible Party: University Hospitals, Leicester
ClinicalTrials.gov Identifier: NCT03514615     History of Changes
Other Study ID Numbers: 97807
First Posted: May 2, 2018    Key Record Dates
Last Update Posted: February 7, 2019
Last Verified: February 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Cicatrix
Fibrosis
Pathologic Processes
Albuterol
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Tocolytic Agents
Reproductive Control Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action